Shares of Medeon Biodesign Inc (益安生醫), which makes medical devices for minimally invasive surgeries, tripled in value from Tuesday through Friday after its debut on the Emerging Stock Market, as investors have high hopes for its management team.
The Emerging Stock Market is a preparatory board for the nation’s two main bourses: the Taiwan Stock Exchange and the GRETAI Securities Market. Trading on the smaller board is restricted to securities firms, by means of negotiation, and therefore initial public offerings are not open to public subscription.
On Friday, Medeon Biodesign shares soared to NT$180, compared with its IPO price of NT$58.
The company, under chief executive officer Jang Yue-teh (張有德), has secured the support of major investment funds in the nation’s biomedical industry, with one of Center Laboratories Inc’s (晟德) subsidiaries holding a 33.05 percent stake and YFY Inc’s (永豐餘投資控股) investment arm Taiwan Global BioFund (上智生技創投) owning 36.43 percent, according to Medeon Biodesign vice president Chen Yi-ju (陳怡如).
Jang, a doctorate holder in materials science from the University of Utah, had served as CEO of another medical device supplier Kyphon Inc, which was acquired by the world’s third-largest medical device company, Medtronic Inc, for US$3.9 billion in 2007.
Medeon Biodesign currently has three products in its pipeline ready for clinical trials and pilot production, Jang told investors on Tuesday, adding that the company is in talks with other companies for licensing of the products.
“The risk for developing a new medical device is significantly reduced after the device completes animal testing and is ready for clinical trials. This is when we talk with global firms to take over the products,.” Jang said. “The role for Medeon Biodesign is to be a partner to global firms with sales channels.”
By cooperating with global firms, the company can shorten time to market and time to peak sales of its products, allowing the company to make profits before its competitors come up with similar devices, Jang said.
Compared with new drugs, sales for a new medical device are lower than a drug, but the risk for developing a medical device is also lower, Jang said.
Center Laboratories chairman Lin Rong-jin (林榮錦) said Medeon Biodesign would spend NT$150 million (US$4.72 million) on research and development a year, hoping that it would develop five products every three years and successfully license at least two of those products.
Medeon Biodesign develops new medical devices by cooperating with doctors in the US and paying attention to their needs, Jang said.
The company will shift its listing to the GRETAI Securities Market by the end of next year, Jang said.
In the first half of this year, the company posted losses of NT$25.89 million, or NT$0.66 per share, according to its filing with the Taiwan Stock Exchange.
Taiwan Transport and Storage Corp (TTS, 台灣通運倉儲) yesterday unveiled its first electric tractor unit — manufactured by Volvo Trucks — in a ceremony in Taipei, and said the unit would soon be used to transport cement produced by Taiwan Cement Corp (TCC, 台灣水泥). Both TTS and TCC belong to TCC International Holdings Ltd (台泥國際集團). With the electric tractor unit, the Taipei-based cement firm would become the first in Taiwan to use electric vehicles to transport construction materials. TTS chairman Koo Kung-yi (辜公怡), Volvo Trucks vice president of sales and marketing Johan Selven, TCC president Roman Cheng (程耀輝) and Taikoo Motors Group
Among the rows of vibrators, rubber torsos and leather harnesses at a Chinese sex toys exhibition in Shanghai this weekend, the beginnings of an artificial intelligence (AI)-driven shift in the industry quietly pulsed. China manufactures about 70 percent of the world’s sex toys, most of it the “hardware” on display at the fair — whether that be technicolor tentacled dildos or hyper-realistic personalized silicone dolls. Yet smart toys have been rising in popularity for some time. Many major European and US brands already offer tech-enhanced products that can enable long-distance love, monitor well-being and even bring people one step closer to
RECORD-BREAKING: TSMC’s net profit last quarter beat market expectations by expanding 8.9% and it was the best first-quarter profit in the chipmaker’s history Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), which counts Nvidia Corp as a key customer, yesterday said that artificial intelligence (AI) server chip revenue is set to more than double this year from last year amid rising demand. The chipmaker expects the growth momentum to continue in the next five years with an annual compound growth rate of 50 percent, TSMC chief executive officer C.C. Wei (魏哲家) told investors yesterday. By 2028, AI chips’ contribution to revenue would climb to about 20 percent from a percentage in the low teens, Wei said. “Almost all the AI innovators are working with TSMC to address the
FUTURE PLANS: Although the electric vehicle market is getting more competitive, Hon Hai would stick to its goal of seizing a 5 percent share globally, Young Liu said Hon Hai Precision Industry Co (鴻海精密), a major iPhone assembler and supplier of artificial intelligence (AI) servers powered by Nvidia Corp’s chips, yesterday said it has introduced a rotating chief executive structure as part of the company’s efforts to cultivate future leaders and to enhance corporate governance. The 50-year-old contract electronics maker reported sizable revenue of NT$6.16 trillion (US$189.67 billion) last year. Hon Hai, also known as Foxconn Technology Group (富士康科技集團), has been under the control of one man almost since its inception. A rotating CEO system is a rarity among Taiwanese businesses. Hon Hai has given leaders of the company’s six